Lon Schneider, MD

Professor of Psychiatry & the Behavioral Sciences

Della Martin Chair in Psychiatry and Neuroscience

Image of Lon Schneider, MD
Is this your profile? Click to edit

Overview

Lon S. Schneider, MD, MS, is professor of psychiatry, neurology, and gerontology at the Keck School of Medicine and Leonard Davis School of Gerontology of the University of Southern California; and holds the Della Martin Chair in Psychiatry and Neuroscience. He directs the USC California Alzheimer’s Disease Center (California Department of Health Services), the Geriatric Studies Center, and co-directs the clinical core of the USC NIA Alzheimer’s Disease Research Center. He holds a master’s degree in applied biometry and epidemiology. His work involves treatment development with novel metabolic and neuroregenerative compounds, outcomes assessment, and approaches to modelling, clinical trials methods and simulations, and, recently, in silico screening of medications for slowing Alzheimer’s disease. He is an associate editor or editorial board member of several publications, and serves on The Lancet Commission on dementia prevention, intervention, and care. He is a Fellow of the American College of Neuropsychopharmacology, and a Distinguished Life Fellow of the American Psychiatric Association.

Awards

  • Woodward/White, Inc.: The Best Doctors in America, 1992-2009

Publications

  • Association Between Self- and Proxy-Reported Depression and Quality of Life in Mild-Moderate Alzheimer’s Disease Am J Geriatr Psychiatry. 2024 01; 32(1):58-67. . View in PubMed
  • Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials J Neurol Neurosurg Psychiatry. 2023 Dec 14; 95(1):2-7. . View in PubMed
  • What the Gantenerumab Trials Teach Us about Alzheimer’s Treatment N Engl J Med. 2023 Nov 16; 389(20):1918-1920. . View in PubMed
  • Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK , GRB14 , and KIAA0825 as novel risk loci for Alzheimer’s disease: the Alzheimer’s Disease Genetics Consortium medRxiv. 2023 Jul 08. . View in PubMed
  • The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents World Psychiatry. 2023 Feb; 22(1):48-74. . View in PubMed
  • The small HDL particle hypothesis of Alzheimer’s disease Alzheimers Dement. 2023 02; 19(2):391-404. . View in PubMed
  • The relationship of history of psychiatric and substance use disorders on risk of dementia among racial and ethnic groups in the United States Front Psychiatry. 2023; 14:1165262. . View in PubMed
  • Reliability of the NACC Telephone-administered Neuropsychological Battery (T-cog) and Montreal Cognitive Assessment for participants in the USC ADRC Alzheimers Dement (Amst). 2023 Jan-Mar; 15(1):e12406. . View in PubMed
  • A phase 1b randomized clinical trial of CT1812 to measure Aß oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter Transl Neurodegener. 2023 05 12; 12(1):24. . View in PubMed
  • Alzheimer’s and Dementia Guidelines and Tables Psychopharmacol Bull. 2023 07 12; 53(2):8-65. . View in PubMed
  • Viewpoint: When It Comes to Lecanemab (and Donanemab), How Might We Think about ‘Reasonable and Necessary’? J Prev Alzheimers Dis. 2023; 10(3):342-343.. View in PubMed
  • The human anti-ganglioside GM1 autoantibody response following traumatic and surgical central nervous system insults Neurosci Res. 2022 Aug; 181:105-114. . View in PubMed
  • The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia Am J Psychiatry. 2022 08; 179(8):519-521. . View in PubMed
  • Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group Lancet Healthy Longev. 2022 07; 3(7):e501-e512. . View in PubMed
  • Committee on High-quality Alzheimer’s Disease Studies (CHADS) consensus report Alzheimers Dement. 2022 06; 18(6):1109-1118. . View in PubMed
  • Diversity in Alzheimer’s disease drug trials: The importance of eligibility criteria Alzheimers Dement. 2022 04; 18(4):810-823. . View in PubMed
  • Diversity in Alzheimer’s disease drug trials: Reflections on reporting and social construction of race Alzheimers Dement. 2022 04; 18(4):867-868. . View in PubMed
  • Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon-like peptide-1 receptor agonists Alzheimers Dement. 2022 03; 18(3):478-497. . View in PubMed
  • The Current Landscape of Prevention Trials in Dementia Neurotherapeutics. 2022 01; 19(1):228-247. . View in PubMed
  • Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer’s disease Alzheimers Dement (N Y). 2022; 8(1):e12286. . View in PubMed
  • Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer’s disease: Structural effects and functional connectivity outcomes Alzheimers Dement (N Y). 2022; 8(1):e12258. . View in PubMed
  • Editorial: Aducanumab Trials EMERGE But Don’t ENGAGE J Prev Alzheimers Dis. 2022; 9(2):193-196. . View in PubMed
  • The Current Landscape of Prevention Trials in Dementia Neurotherapeutics. 2022 Jan; 19(1):228-247. . View in PubMed
  • High Soluble Amyloid-ß42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations J Alzheimers Dis. 2022; 90(1):333-348. . View in PubMed
  • Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial J Prev Alzheimers Dis. 2022; 9(4):625-634. . View in PubMed
  • A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease J Prev Alzheimers Dis. 2022; 9(2):247-254. . View in PubMed
  • High cerebrospinal amyloid-ß 42 is associated with normal cognition in individuals with brain amyloidosis EClinicalMedicine. 2021 Aug; 38:100988. . View in PubMed
  • The efficacy of antidepressant medication and interpersonal psychotherapy for adult acute-phase depression: study protocol of a systematic review and meta-analysis of individual participant data BJPsych Open. 2021 Feb 19; 7(2):e56. . View in PubMed
  • The need to show minimum clinically important differences in Alzheimer’s disease trials Lancet Psychiatry. 2021 11; 8(11):1013-1016. . View in PubMed
  • Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification Alzheimers Dement. 2021 08; 17(8):1365-1382. . View in PubMed
  • Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2021 07; 20(7):537-547. . View in PubMed
  • Development of novel measures for Alzheimer’s disease prevention trials (NoMAD) Contemp Clin Trials. 2021 07; 106:106425. . View in PubMed
  • Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group Lancet Neurol. 2021 06; 20(6):484-496. . View in PubMed
  • Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults Brain Behav Immun. 2021 05; 94:299-307. . View in PubMed
  • Value-Generating Exploratory Trials in Neurodegenerative Dementias Neurology. 2021 05 18; 96(20):944-954. . View in PubMed
  • Impact of potential modifications to Alzheimer’s disease clinical trials in response to disruption by COVID-19: a simulation study Alzheimers Res Ther. 2021 12 20; 13(1):201. . View in PubMed
  • Soluble Amyloid-ß Consumption in Alzheimer’s Disease J Alzheimers Dis. 2021; 82(4):1403-1415. . View in PubMed
  • Alzheimer’s drugs: Does reducing amyloid work? Science. 2021 10 29; 374(6567):544-545.. View in PubMed
  • Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial EBioMedicine. 2020 Sep; 59:102883. . View in PubMed
  • A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid Alzheimers Dement. 2020 06; 16(6):821-830. . View in PubMed
  • APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline Nature. 2020 05; 581(7806):71-76. . View in PubMed
  • Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy Menopause. 2020 01; 27(1):57-65. . View in PubMed
  • Using practice effects for targeted trials or sub-group analysis in Alzheimer’s disease: How practice effects predict change over time PLoS One. 2020; 15(2):e0228064. . View in PubMed
  • Pragmatic Trials and Repurposed Drugs for Alzheimer Disease JAMA Neurol. 2020 02 01; 77(2):162-163. . View in PubMed
  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease Alzheimers Res Ther. 2020 03 02; 12(1):21. . View in PubMed
  • Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet. 2020 08 08; 396(10248):413-446. . View in PubMed
  • Commentary: The EU/US Task Force’s Future for Anti-Amyloid Trials: Faites Vos Jeux J Prev Alzheimers Dis. 2020; 7(3):199-200. . View in PubMed
  • Response to peer commentaries: Composite cognitive and functional measures for early stage Alzheimer’s disease trials Alzheimers Dement (Amst). 2020; 12(1):e12024. . View in PubMed
  • Progression of Alzheimer’s Disease by Self-Reported Cancer History in the Alzheimer’s Disease Neuroimaging Initiative J Alzheimers Dis. 2020; 76(2):691-701. . View in PubMed
  • Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer’s disease: A single and multiple ascending dose phase 1b/2a clinical trial Alzheimers Dement (N Y). 2020; 6(1):e12107. . View in PubMed
  • Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid J Neurosci. 2020 10 28; 40(44):8573-8586. . View in PubMed
  • Composite cognitive and functional measures for early stage Alzheimer’s disease trials Alzheimers Dement (Amst). 2020; 12(1):e12017. . View in PubMed
  • Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial JAMA Neurol. 2019 Nov 01; 76(11):1330-1339. . View in PubMed
  • Treatment Options for Agitation in Dementia Curr Treat Options Neurol. 2019 Jun 24; 21(7):30. . View in PubMed
  • Escitalopram for agitation in Alzheimer’s disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial Alzheimers Dement. 2019 11; 15(11):1427-1436. . View in PubMed
  • The risks and uses of dietary supplements Lancet Neurol. 2019 09; 18(9):814. . View in PubMed
  • Safety and feasibility of estrogen receptor-ß targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial Menopause. 2019 08; 26(8):874-884. . View in PubMed
  • A randomized clinical trial to evaluate home-based assessment of people over 75 years old Alzheimers Dement. 2019 05; 15(5):615-624. . View in PubMed
  • Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need Alzheimers Dement. 2019 02; 15(2):292-312. . View in PubMed
  • Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction Nat Med. 2019 02; 25(2):270-276. . View in PubMed
  • Vascular dysfunction-The disregarded partner of Alzheimer’s disease Alzheimers Dement. 2019 01; 15(1):158-167. . View in PubMed
  • Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial Neurology. 2019 10 08; 93(15):e1474-e1484. . View in PubMed
  • A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease Alzheimers Dement (N Y). 2019; 5:20-26. . View in PubMed
  • Evaluation of Medicare Claims Data as a Tool to Identify Dementia J Alzheimers Dis. 2019; 67(2):769-778. . View in PubMed
  • Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer’s Disease Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457. . View in PubMed
  • Precision pharmacology for Alzheimer’s disease Pharmacol Res. 2018 04; 130:331-365. . View in PubMed
  • Pimavanserin for patients with Alzheimer’s disease psychosis Lancet Neurol. 2018 03; 17(3):194-195. . View in PubMed
  • Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ß-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women Menopause. 2018 02; 25(2):191-196. . View in PubMed
  • The Alzheimer’s Prevention Initiative Autosomal-Dominant Alzheimer’s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort Alzheimers Dement (N Y). 2018; 4:150-160. . View in PubMed
  • Data-driven identification of endophenotypes of Alzheimer’s disease progression: implications for clinical trials and therapeutic interventions Alzheimers Res Ther. 2018 01 15; 10(1):4. . View in PubMed
  • Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis JAMA Netw Open. 2018 11 02; 1(7):e184080. . View in PubMed
  • (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease Curr Alzheimer Res. 2018; 15(9):883-891. . View in PubMed
  • Analysis of shared heritability in common disorders of the brain Science. 2018 06 22; 360(6395). . View in PubMed
  • Dementia prevention, intervention, and care Lancet. 2017 Dec 16; 390(10113):2673-2734. . View in PubMed
  • Challenging Assumptions About African American Participation in Alzheimer Disease Trials Am J Geriatr Psychiatry. 2017 Oct; 25(10):1150-1159. . View in PubMed
  • Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E e4 Carriers: A Review JAMA Neurol. 2017 Mar 01; 74(3):339-347. . View in PubMed
  • Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease Alzheimers Res Ther. 2017 Feb 17; 9(1):10. . View in PubMed
  • Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease Nat Genet. 2017 09; 49(9):1373-1384. . View in PubMed
  • Lessons from the Multidomain Alzheimer Preventive Trial Lancet Neurol. 2017 08; 16(8):585-586. . View in PubMed
  • Dementia research priorities-1 – Author’s reply Lancet Neurol. 2017 03; 16(3):181. . View in PubMed
  • Dementia research priorities-2 – Author’s reply Lancet Neurol. 2017 03; 16(3):182. . View in PubMed
  • Alzheimer’s disease and other dementias: update on research Lancet Neurol. 2017 01; 16(1):4-5. . View in PubMed
  • The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design and disease progression model Alzheimers Dement. 2017 01; 13(1):8-19. . View in PubMed
  • Characterizing Highly Benefited Patients in Randomized Clinical Trials Int J Biostat. 2017 05 20; 13(1). . View in PubMed
  • Guideline Watch (October 2014): Practice Guideline for the Treatment of Patients With Alzheimer’s Disease and Other Dementias Focus (Am Psychiatr Publ). 2017 Jan; 15(1):110-128. . View in PubMed
  • Preventing Dementia: Many Issues and Not Enough Time JAMA Neurol. 2017 05 01; 74(5):508-510. . View in PubMed
  • Reduce vascular risk to prevent dementia? Lancet. 2016 Aug 20; 388(10046):738-40.. View in PubMed
  • Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer’s Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial Am J Psychiatry. 2016 May 01; 173(5):465-72. . View in PubMed
  • Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer’s Dementia: Evidence From the CitAD Study Am J Psychiatry. 2016 May 01; 173(5):473-80. . View in PubMed
  • Defeating Alzheimer’s disease and other dementias: a priority for European science and society Lancet Neurol. 2016 Apr; 15(5):455-532. . View in PubMed
  • Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease J Psychiatr Res. 2016 Mar; 74:17-21. . View in PubMed
  • Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64. . View in PubMed
  • Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria Alzheimers Dement. 2016 Mar; 12(3):292-323. . View in PubMed
  • A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation J Pharmacokinet Pharmacodyn. 2016 Feb; 43(1):99-109. . View in PubMed
  • WHO’s dementia research priorities: a prescription for failure? Lancet Neurol. 2016 11; 15(12):1202-1203.. View in PubMed
  • R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation Br J Clin Pharmacol. 2016 09; 82(3):784-92. . View in PubMed
  • Principal components analysis of agitation outcomes in Alzheimer’s disease J Psychiatr Res. 2016 08; 79:4-7. . View in PubMed
  • Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials Parkinsonism Relat Disord. 2016 07; 28:41-48. . View in PubMed
  • Mortality risk in current and new antipsychotic Alzheimer’s disease users: Large scale Japanese study Alzheimers Dement. 2016 07; 12(7):823-30. . View in PubMed
  • Accelerating stem cell trials for Alzheimer’s disease Lancet Neurol. 2016 02; 15(2):219-230. . View in PubMed
  • Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials J Alzheimers Dis. 2016; 50(4):1205-15. . View in PubMed
  • The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease Alzheimers Res Ther. 2016 06 30; 8:25. . View in PubMed
  • Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial Lancet. 2016 12 10; 388(10062):2873-2884. . View in PubMed
  • Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial Int Psychogeriatr. 2015 Dec; 27(12):2059-67. . View in PubMed
  • Treatment changes among older patients with dementia treated with antipsychotics Int J Geriatr Psychiatry. 2015 Dec; 30(12):1238-49. . View in PubMed
  • Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33. . View in PubMed
  • Estimating Mortality Associated With Antipsychotics and Other Psychotropics–Reply JAMA Psychiatry. 2015 Oct; 72(10):1058. . View in PubMed
  • Effect of sample size re-estimation in adaptive clinical trials for Alzheimer’s disease and mild cognitive impairment Alzheimers Dement (N Y). 2015 Jun; 1(1):63-71. . View in PubMed
  • Using baseline cognitive severity for enriching Alzheimer’s disease clinical trials: How does Mini-Mental State Examination predict rate of change? Alzheimers Dement (N Y). 2015 Jun; 1(1):46-52.. View in PubMed
  • Introducing Alzheimer’s & Dementia: Translational Research & Clinical Interventions, an open access journal of the Alzheimer’s Association Alzheimers Dement (N Y). 2015 Jun; 1(1):91-93. . View in PubMed
  • Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm JAMA Psychiatry. 2015 May; 72(5):438-45. . View in PubMed
  • Differences in Alzheimer disease clinical trial outcomes based on age of the participants Neurology. 2015 Mar 17; 84(11):1121-7. . View in PubMed
  • Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer’s disease randomized controlled trials Alzheimers Dement (Amst). 2015 Mar; 1(1):103-11. . View in PubMed
  • Rarity of the Alzheimer disease-protective APP A673T variant in the United States JAMA Neurol. 2015 Feb; 72(2):209-16. . View in PubMed
  • Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. . View in PubMed
  • Adverse events and dropouts in Alzheimer’s disease studies: what can we learn? Alzheimers Dement. 2015 Jan; 11(1):24-31.. View in PubMed
  • Idalopirdine for Alzheimer’s disease: written in the stars Lancet Neurol. 2014 Nov; 13(11):1063-1065. . View in PubMed
  • Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study JAMA Neurol. 2014 Nov; 71(11):1394-404. . View in PubMed
  • 2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. . View in PubMed
  • Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative Neurology. 2014 Jul 22; 83(4):364-73. . View in PubMed
  • Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial Lancet Neurol. 2014 Jul; 13(7):676-85. . View in PubMed
  • Alzheimer’s Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. . View in PubMed
  • Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer’s disease Alzheimers Dement. 2014 May; 10(3):349-59. . View in PubMed
  • Rethinking the Food and Drug Administration’s 2013 guidance on developing drugs for early-stage Alzheimer’s disease Alzheimers Dement. 2014 Mar; 10(2):247-50. . View in PubMed
  • Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial JAMA. 2014 Feb 19; 311(7):682-91. . View in PubMed
  • A new roadmap for drug development for Alzheimer’s disease Nat Rev Drug Discov. 2014 Feb; 13(2):156. . View in PubMed
  • Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24. . View in PubMed
  • Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial PLoS One. 2014; 9(6):e98426. . View in PubMed
  • Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future Alzheimers Dement. 2013 Sep; 9(5):602-8. . View in PubMed
  • Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. . View in PubMed
  • Moderators of outcome in late-life depression: a patient-level meta-analysis Am J Psychiatry. 2013 Jun; 170(6):651-9. . View in PubMed
  • Alzheimer disease pharmacologic treatment and treatment research Continuum (Minneap Minn). 2013 Apr; 19(2 Dementia):339-57. . View in PubMed
  • Quantifying an amyloid ß model for Alzheimer’s disease Lancet Neurol. 2013 Apr; 12(4):327-8. . View in PubMed
  • Early intervention with an estrogen receptor ß-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer’s disease J Alzheimers Dis. 2013; 37(2):403-19. . View in PubMed
  • Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44. . View in PubMed
  • Ginkgo and AD: key negatives and lessons from GuidAge Lancet Neurol. 2012 Oct; 11(10):836-7. . View in PubMed
  • Novel late-onset Alzheimer disease loci variants associate with brain gene expression Neurology. 2012 Jul 17; 79(3):221-8. . View in PubMed
  • Recruitment methods for United States Alzheimer disease prevention trials J Nutr Health Aging. 2012 Apr; 16(4):331-5. . View in PubMed
  • Caregiver burden, health utilities, and institutional service use in Alzheimer’s disease Int J Geriatr Psychiatry. 2012 Apr; 27(4):382-93. . View in PubMed
  • Discontinuing donepezil or starting memantine for Alzheimer’s disease N Engl J Med. 2012 Mar 08; 366(10):957-9. . View in PubMed
  • Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. . View in PubMed
  • Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. . View in PubMed
  • Biomarker positive and negative subjects in the ADNI cohort: clinical characterization Curr Alzheimer Res. 2012 12; 9(10):1135-41. . View in PubMed
  • Risk of mortality among individual antipsychotics in patients with dementia Am J Psychiatry. 2012 Jan; 169(1):71-9. . View in PubMed
  • Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease J Clin Psychiatry. 2012 Jan; 73(1):121-8. . View in PubMed
  • Citalopram for agitation in Alzheimer’s disease: design and methods Alzheimers Dement. 2012; 8(2):121-30. . View in PubMed
  • Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress Free Radic Biol Med. 2011 Dec 01; 51(11):2007-17. . View in PubMed
  • Sertraline for the treatment of depression in Alzheimer disease: genetic influences J Geriatr Psychiatry Neurol. 2011 Dec; 24(4):222-8. . View in PubMed
  • Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study J Clin Pharmacol. 2011 Nov; 51(11):1587-91. . View in PubMed
  • Estrogen receptor ß-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause Menopause. 2011 Oct; 18(10):1131-42. . View in PubMed
  • Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. . View in PubMed
  • Lack of evidence for the efficacy of memantine in mild Alzheimer disease Arch Neurol. 2011 Aug; 68(8):991-8. . View in PubMed
  • Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD Am J Psychiatry. 2011 Aug; 168(8):831-9. . View in PubMed
  • Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons Mol Neurodegener. 2011 Jun 01; 6:37. . View in PubMed
  • Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)? Int J Geriatr Psychiatry. 2011 Jun; 26(6):573-83.. View in PubMed
  • Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease Nat Genet. 2011 May; 43(5):436-41. . View in PubMed
  • Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. . View in PubMed
  • Trends in antipsychotic use in dementia 1999-2007 Arch Gen Psychiatry. 2011 Feb; 68(2):190-7. . View in PubMed
  • Predictors of nursing home admission among Alzheimer’s disease patients with psychosis and/or agitation Int Psychogeriatr. 2011 Feb; 23(1):44-53. . View in PubMed
  • Anti-aß therapeutics in Alzheimer’s disease: the need for a paradigm shift Neuron. 2011 Jan 27; 69(2):203-13. . View in PubMed
  • Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer’s Disease Neuroimaging Initiative Arch Neurol. 2011 Jan; 68(1):58-66. . View in PubMed
  • Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer’s disease trial J Clin Psychopharmacol. 2010 Dec; 30(6):683-7. . View in PubMed
  • Fixing Alzheimer disease trials by improving process and methods Curr Alzheimer Res. 2010 Nov; 7(7):564-5. . View in PubMed
  • Organising the language of Alzheimer’s disease in light of biomarkers Lancet Neurol. 2010 Nov; 9(11):1044-5. . View in PubMed
  • Caregiver burden, health utilities, and institutional service costs among community-dwelling patients with Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Oct-Dec; 24(4):380-9. . View in PubMed
  • Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates Am J Geriatr Psychiatry. 2010 Oct; 18(10):917-27. . View in PubMed
  • Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement. 2010 Sep; 6(5):367-77. . View in PubMed
  • Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson’s disease Mol Neurodegener. 2010 Apr 13; 5:14. . View in PubMed
  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations J Nutr Health Aging. 2010 Apr; 14(4):295-8. . View in PubMed
  • Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes Am J Geriatr Psychiatry. 2010 Apr; 18(4):332-40. . View in PubMed
  • Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. . View in PubMed
  • Sertraline for the treatment of depression in Alzheimer disease Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45. . View in PubMed
  • Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA. 2009 Dec 16; 302(23):2557-64. . View in PubMed
  • Current Alzheimer’s disease clinical trials: methods and placebo outcomes Alzheimers Dement. 2009 Sep; 5(5):388-97. . View in PubMed
  • Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials Alzheimer Dis Assoc Disord. 2009 Jul-Sep; 23(3):260-7. . View in PubMed
  • Anxiety does not predict response to antidepressant treatment in late life depression: results of a meta-analysis Int J Geriatr Psychiatry. 2009 May; 24(5):539-44. . View in PubMed
  • Metabolic changes associated with second-generation antipsychotic use in Alzheimer’s disease patients: the CATIE-AD study Am J Psychiatry. 2009 May; 166(5):583-90. . View in PubMed
  • Commentary on “a roadmap for the prevention of dementia II: Leon Thal Symposium 2008” A federally funded corporation for the prevention and treatment of cognitive impairment and brain aging. Alzheimers Dement. 2009 Mar; 5(2):172-9. . View in PubMed
  • A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. . View in PubMed
  • The perils of Alzheimer’s drug development Curr Alzheimer Res. 2009 Feb; 6(1):77-8. . View in PubMed
  • Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer’s disease Int J Geriatr Psychiatry. 2009 Jan; 24(1):96-105. . View in PubMed
  • Sociodemographic and clinical correlates of utility scores in Alzheimer’s disease Value Health. 2008 Dec; 11(7):1120-30. . View in PubMed
  • Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity Mol Brain. 2008 Nov 21; 1:17. . View in PubMed
  • Ginkgo biloba extract and preventing Alzheimer disease JAMA. 2008 Nov 19; 300(19):2306-8. . View in PubMed
  • Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia Schizophr Res. 2008 Nov; 106(1):33-41. . View in PubMed
  • High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA. 2008 Oct 15; 300(15):1774-83. . View in PubMed
  • Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial Am J Psychiatry. 2008 Jul; 165(7):844-54. . View in PubMed
  • Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence Am J Geriatr Psychiatry. 2008 Jul; 16(7):558-67. . View in PubMed
  • Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria Am J Geriatr Psychiatry. 2008 Jun; 16(6):469-77. . View in PubMed
  • A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. . View in PubMed
  • Does donepezil improve executive function in patients with CADASIL? Lancet Neurol. 2008 Apr; 7(4):287-9.. View in PubMed
  • Sex, race, and smoking impact olanzapine exposure J Clin Pharmacol. 2008 Feb; 48(2):157-65. . View in PubMed
  • Prevention therapeutics of dementia Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S122-30. . View in PubMed
  • American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementiasSecond edition. Am J Psychiatry. 2007 Dec; 164(12 Suppl):5-56. . View in PubMed
  • Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease Arch Gen Psychiatry. 2007 Nov; 64(11):1259-68. . View in PubMed
  • Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials Lancet Neurol. 2007 Sep; 6(9):782-92. . View in PubMed
  • National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer’s Disease (CATIE-AD): baseline characteristics Curr Alzheimer Res. 2007 Jul; 4(3):325-35. . View in PubMed
  • Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer’s disease? Curr Alzheimer Res. 2007 Jul; 4(3):273-6.. View in PubMed
  • Commentary on “Meta-analysis of six-month memantine trials in Alzheimer’s disease” Wuthering forest plots: distinguishing the forest from the plots. Alzheimers Dement. 2007 Jan; 3(1):18-20. . View in PubMed
  • Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment Mitochondrion. 2006 Dec; 6(6):323-30. . View in PubMed
  • Design of Depression in Alzheimer’s Disease Study-2 Am J Geriatr Psychiatry. 2006 Nov; 14(11):920-30. . View in PubMed
  • Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice Brain Res. 2006 Oct 20; 1116(1):194-200. . View in PubMed
  • Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease N Engl J Med. 2006 Oct 12; 355(15):1525-38. . View in PubMed
  • ADCS Prevention Instrument Project: ADCS-clinicians’ global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S124-38. . View in PubMed
  • Open-label extension studies and misinformation Arch Neurol. 2006 Jul; 63(7):1036; author reply 1036-7. . View in PubMed
  • Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials Am J Geriatr Psychiatry. 2006 Mar; 14(3):191-210. . View in PubMed
  • Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91. . View in PubMed
  • The post-modern world of Alzheimer’s disease trials: how much is an ADAS-cog point worth in central London? Int J Geriatr Psychiatry. 2006 Jan; 21(1):9-13.. View in PubMed
  • A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type Curr Alzheimer Res. 2005 Dec; 2(5):541-51. . View in PubMed
  • Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials JAMA. 2005 Oct 19; 294(15):1934-43. . View in PubMed
  • Drug development, clinical trials, cultural heterogeneity in Alzheimer disease: the need for pro-active recruitment Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):279-83. . View in PubMed
  • Mild cognitive impairment Am J Geriatr Psychiatry. 2005 Aug; 13(8):629-32. . View in PubMed
  • Meta-analysis of memantine: summary and commentary on the Cochrane Collaboration’s systematic review Alzheimers Dement. 2005 Jul; 1(1):67-71. . View in PubMed
  • Symptoms of late-life depression: frequency and change during treatment Am J Geriatr Psychiatry. 2005 Jun; 13(6):520-6. . View in PubMed
  • Clinical application of operationalized criteria for ‘Depression of Alzheimer’s Disease’ Int J Geriatr Psychiatry. 2005 Feb; 20(2):119-27. . View in PubMed
  • Recognizing and responding to atypical antipsychotic side effects J Am Med Dir Assoc. 2004 Jul-Aug; 5(4 Suppl):H7-10. . View in PubMed
  • AD2000: donepezil in Alzheimer’s disease Lancet. 2004 Jun 26; 363(9427):2100-1. . View in PubMed
  • Estrogen and dementia: insights from the Women’s Health Initiative Memory Study JAMA. 2004 Jun 23; 291(24):3005-7. . View in PubMed
  • Delay in nursing home placement with donepezil J Am Geriatr Soc. 2004 Jun; 52(6):1024-6; author reply 1026-7. . View in PubMed
  • Venlafaxine offers no benefit over sertraline and is less well tolerated in depressed nursing home residents Evid Based Ment Health. 2004 May; 7(2):47. . View in PubMed
  • Psychosis of Alzheimer’s disease: clinical characteristics and history J Psychiatr Res. 2004 Jan; 38(1):105-11. . View in PubMed
  • Evidence-based practices in geriatric mental health care: an overview of systematic reviews and meta-analyses Psychiatr Clin North Am. 2003 Dec; 26(4):971-90x-xi. . View in PubMed
  • Cholinesterase inhibitors for vascular dementia? Lancet Neurol. 2003 Nov; 2(11):658-9.. View in PubMed
  • Efficacy of controlled-release paroxetine in the treatment of late-life depression J Clin Psychiatry. 2003 Sep; 64(9):1065-74. . View in PubMed
  • Choosing treatment for Alzheimer’s patients and their caregivers Geriatrics. 2003 Aug; 58 Suppl 1:3-1823; quiz 19-22. . View in PubMed
  • An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression Am J Psychiatry. 2003 Jul; 160(7):1277-85. . View in PubMed
  • Psychosis of Alzheimer disease: validity of the construct and response to risperidone Am J Geriatr Psychiatry. 2003 Jul-Aug; 11(4):414-25. . View in PubMed
  • Cholinesterase inhibitors for Alzheimer disease JAMA. 2003 May 14; 289(18):2359-60; author reply 2360-1. . View in PubMed
  • A critical analysis of new molecular targets and strategies for drug developments in Alzheimer’s disease Curr Drug Targets. 2003 Feb; 4(2):97-112. . View in PubMed
  • Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review Expert Rev Neurother. 2003 01; 3(1):99-106. . View in PubMed
  • Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer’s disease trial Schizophr Bull. 2003; 29(1):57-72. . View in PubMed
  • The increasing power of placebos in trials of antidepressants JAMA. 2002 Jul 24-31; 288(4):450. . View in PubMed
  • Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):129-41. . View in PubMed
  • Provisional diagnostic criteria for depression of Alzheimer disease Am J Geriatr Psychiatry. 2002 Mar-Apr; 10(2):125-8. . View in PubMed
  • Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer’s disease J Neuropsychiatry Clin Neurosci. 2002; 14(3):303-10. . View in PubMed
  • Treatment of Alzheimer’s disease with cholinesterase inhibitors Clin Geriatr Med. 2001 May; 17(2):337-58. . View in PubMed
  • National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology Am J Geriatr Psychiatry. 2001; 9(4):346-60. . View in PubMed
  • Antidepressant Treatment of Very Old Patients Am J Geriatr Psychiatry. 1993 Winter; 1(1):21-29. . View in PubMed